Log in
NASDAQ:VTGN

Vistagen Therapeutics Stock Forecast, Price & News

$0.70
+0.03 (+4.50 %)
(As of 09/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.66
Now: $0.70
$0.75
50-Day Range
$0.59
MA: $0.67
$0.90
52-Week Range
$0.29
Now: $0.70
$1.49
Volume1.34 million shs
Average Volume1.19 million shs
Market Capitalization$54.36 million
P/E RatioN/A
Dividend YieldN/A
Beta0.53
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of drug rescue NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.
Read More
Vistagen Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.21 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTGN
CUSIPN/A
Phone650-577-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.12) per share

Profitability

Net Income$-20,770,000.00

Miscellaneous

Employees9
Market Cap$54.36 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$0.70
+0.03 (+4.50 %)
(As of 09/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

How has Vistagen Therapeutics' stock been impacted by COVID-19?

Vistagen Therapeutics' stock was trading at $0.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VTGN shares have increased by 39.4% and is now trading at $0.6970.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Vistagen Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Vistagen Therapeutics
.

When is Vistagen Therapeutics' next earnings date?

Vistagen Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Vistagen Therapeutics
.

How were Vistagen Therapeutics' earnings last quarter?

Vistagen Therapeutics Inc (NASDAQ:VTGN) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.07).
View Vistagen Therapeutics' earnings history
.

What price target have analysts set for VTGN?

3 equities research analysts have issued 1-year target prices for Vistagen Therapeutics' shares. Their forecasts range from $0.70 to $3.00. On average, they expect Vistagen Therapeutics' share price to reach $1.85 in the next year. This suggests a possible upside of 165.4% from the stock's current price.
View analysts' price targets for Vistagen Therapeutics
.

Who are some of Vistagen Therapeutics' key competitors?

What other stocks do shareholders of Vistagen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), Yamana Gold (AUY), Crispr Therapeutics (CRSP) and SCYNEXIS (SCYX).

Who are Vistagen Therapeutics' key executives?

Vistagen Therapeutics' management team includes the following people:
  • Mr. Shawn K. Singh, CEO & Director (Age 56)
  • Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 69)
  • Mr. Jerrold D. Dotson, CFO, VP & Sec. (Age 66)
  • Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 53)
  • Dr. Mark A. Smith, Chief Medical Officer (Age 64)

What is Vistagen Therapeutics' stock symbol?

Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

How do I buy shares of Vistagen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vistagen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $0.70.

How big of a company is Vistagen Therapeutics?

Vistagen Therapeutics has a market capitalization of $54.36 million. The company earns $-20,770,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe.

What is Vistagen Therapeutics' official website?

The official website for Vistagen Therapeutics is www.vistagen.com.

How can I contact Vistagen Therapeutics?

Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.